Amundi’s Pacira BioSciences PCRX Stock Holding History

Amundi’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$403K	Buy	15,894 +2,210	+16%	+$52.2K	﹤0.01%	1726
2026 Q1	$309K	Buy	+13,684	New	+$304K	﹤0.01%	1733
2025 Q2	–	Sell	-18,723	Closed	-$455K	–	2039
2025 Q1	$455K	Sell	18,723 -4,391	-19%	-$105K	﹤0.01%	1512
2024 Q4	$429K	Buy	23,114 +15,431	+201%	+$271K	﹤0.01%	1591
2024 Q3	$120K	Buy	7,683 +711	+10%	+$12.2K	﹤0.01%	1755
2024 Q2	$151K	Buy	+6,972	New	+$198K	﹤0.01%	1633
2022 Q4	–	Sell	-2,635	Closed	-$149K	–	1956
2022 Q3	$149K	Hold	2,635	–	–	﹤0.01%	1498
2022 Q2	$139K	Hold	2,635	–	–	﹤0.01%	1400
2022 Q1	$214K	Hold	2,635	–	–	﹤0.01%	1380
2021 Q4	$162K	Hold	2,635	–	–	﹤0.01%	1507
2021 Q3	$148K	Hold	2,635	–	–	﹤0.01%	1476
2021 Q2	$160K	Buy	+2,635	New	+$167K	﹤0.01%	1422

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Amundi's PCRX Position: Q2 2026 in Review

Amundi increased its Pacira BioSciences (PCRX) stake by 16% in Q2 2026, buying an estimated $52.2K and bringing the position to 15,894 shares worth $403K. The position accounts for ﹤0.01% of the portfolio, ranked #1726.

Amundi first reported a position in PCRX in Q2 2021 and has held it in 12 quarters since. The position peaked at $455K in Q1 2025. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Amundi held 15,894 shares of Pacira BioSciences worth $403K as of Q2 2026.
Amundi bought 2,210 Pacira BioSciences shares in Q2 2026, an estimated $52.2K.
Pacira BioSciences made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1726 holding.
Amundi first reported a position in Pacira BioSciences in Q2 2021 and has held it in 12 quarters since.
Amundi's Pacira BioSciences position peaked at $455K in Q1 2025.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.